ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Gilead Sciences to Promote Low-Cost HIV Medicine in Developing World

By Chelsea Stevenson Gilead Sciences Inc. (GILD) said it plans to partner with Mylan Inc. (MYL), Ranbaxy Laboratories Ltd. (500359.BY) and Strides Arcolab Ltd. (532531.BY) to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries. The medicine includes single tablet regimens and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines. Under the new agreement, Gilead will provide a technology transfer for the manufacture of emtricitabine as well as funding to reduce overall manufacturing costs. Emtricitabine is marked by Gilead under the name Emtriva and the fixed-dose is available under the name Truvada. But costs are an obstacle for high-volume production. More than 2.7 million patients living with HIV in developing countries are currently receiving a medicine innovated by Gilead and subsequently licensed to Indian generic partners, as part of the company's efforts to increase global access. Strides Arcolab Managing Director Arun Kumar said the partnership will also re-enforce commitments to provide affordable drugs in the tuberculosis and malaria fields. Gilead's second-quarter earnings slid last week as the company posted a double-digit increase in costs, which offset its strong revenue growth. Earlier this year, the company bought Pharmasset Inc. for more than $11 billion, expecting the company to help accelerate the development of treatments for hepatitis C. Write to Chelsea Stevenson at Subscribe to WSJ:

Stock News for Abbott Labs (ABT)
11/05/201514:41:24Quarterly Report (10-q)
11/03/201508:30:00Zoetis Lifts Outlook as Results Top Views
11/01/201511:23:035 Healthcare Trends to Invest in for the Next 20 Years
10/30/201512:31:00Health is a Marathon, not a Sprint
10/29/201515:52:00'Science' Says Abbott Is a Top Employer
10/28/201519:52:56Your One-Stop Dividend Aristocrat Resource
10/23/201502:04:49The Conservative Total Return Portfolio: 3 Hits And A Miss
10/22/201508:01:00Abbott fait équipe avec Cristiano Ronaldo, star du football...
10/22/201508:01:00Abbott Teams Up with Soccer Star Cristiano Ronaldo to Inspire...
10/22/201508:01:00Abbott Teams Up with Soccer Star Cristiano Ronaldo to Inspire...
10/21/201519:49:00Abbott Teams Up with Football Star Cristiano Ronaldo to Inspire...
10/21/201511:10:00Abbott Labs Profit Rises
10/21/201510:50:00Abbott Labs Profit Rises, Helped by Emerging Markets
10/21/201507:45:00Abbott Reports Third-Quarter 2015 Results
10/20/201517:30:59Notable earnings before Wednesday’s open
10/16/201501:40:00Valeant Probe Reprises Federal Focus on Drug Pricing
10/15/201510:00:00New York Road Runners and Abbott Partner for 2015 TCS New York...
10/12/201516:00:00Abbott Laboratories Dissolving Stent Shows Mixed Results
10/12/201515:57:00Abbott Laboratories Dissolving Stent Shows Mixed Results in Study
10/12/201514:25:00Abbott Announces Positive Clinical Results of Absorb™, the N...

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations